AstraZeneca: Lynparza Trial Has Met Primary Endpoint
June 05 2017 - 2:47AM
Dow Jones News
LONDON--AstraZeneca PLC (AZN.LN) said Monday that the phase 3
trial of treatment drug Lynparza has met its primary endpoint.
The pharmaceutical company said the trial showed a
statistically-significant and clinically-meaningful improvement in
progression-free survival for patients treated with Lynparza
tablets, compared to chemotherapy.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
June 05, 2017 02:32 ET (06:32 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024